Mitigate drug-drug interaction safety risk through access to unprecedented data for FDA and EMA approved drugs

- Optimize first in man dose with precedent data on approved drugs
- Better prioritize clinical DDI studies and avoid doing unnecessary DDI trials
- Improve clinical trial design by inclusion/exclusion based on DDI risk
- Develop strategies to understand and mitigate safety risk with unavoidable comedication

Critical DMPK insights for drug candidate evaluation

To perform the most comprehensive risk-benefit assessment and drug candidate prioritization, you need access to the highest quality DMPK data and DDI analytics.

Regulatory documents contain the highest quality data that has been evaluated and approved of by regulatory authorities. Insights into the preclinical and clinical data of similar drugs are invaluable to support decisions in PK study design, translation of animal model results to human dosage and safety, and prediction of drug-drug interaction risk.

How PharmaPendium helps

PharmaPendium is the most comprehensive database on EMA and FDA approved drugs. PhD/MD level specialists extract high-quality, comparative pharmacokinetic, efficacy, metabolizing enzyme and transporter data on thousands of marketed drugs. Preclinical and clinical data is extracted from the full regulatory approval packages as well as the FDA Advisory committee documents and literature. This enables access to information that otherwise would have been missed.

PharmaPendium data can be retrieved with high precision due to Elsevier’s expert biomedical taxonomies and data is easily exported for use in modeling workflows. Data is linked back to the original full text searchable source documents. This allows the best possible experimental design and streamlined approval based on precedent regulatory feedback.

Answer critical questions:

- What drugs have a similar PK profile as my drug under development?
- What is the best experimental model and design to assess my PK parameters of interest?
- What is the drug-drug interaction risk for my drug under development?
- Which enzymes/transporters are involved in the metabolism of drugs in the same therapeutic class as mine?

Figure 1. Snapshot of available data on the effect of the antifungal Itraconazole on metabolic enzymes. In total, 24 data columns and 95 PK parameters are available.
Compliant DDI risk calculations to inform drug development decisions

PharmaPendium includes a mechanistic static DDI risk calculator (DDIRC) that supports identification of drug–drug interactions between a drug candidate and marketed drugs. It is compliant with the 2020 "In vitro Drug Interaction Studies CYP450 Enzyme and Transporters Mediated interactions FDA Guide". Predictions made were used to successfully answer questions from several regulatory bodies, including the FDA, the EMA and Swissmedic. Because of the extensive marketed drug library, PharmaPendium DDIRC allows fast predictions across hundreds of potential co-medications.

Thereby, PharmaPendium provides high quality early predictions of drug-drug interactions to help avoid costly clinical DDI studies, optimize trial design and reduce the risk of unexpected post market adverse events.

"The comprehensive data increases confidence in DDI predictions."

Department Head Pharmacokinetics and Drug Interaction, Global Pharma Company

PharmaPendium delivers access to:

- 4,6K+ drugs with data in PharmaPendium
- 2,0M+ extracted PK data records on over 95 PK parameters
- 427K+ extracted enzyme and transporter data records: drug as inducer, inhibitor or substrate
- 14M+ FDA post-market reports (FAERS)
- 2,8M+ pages of full text searchable FDA and EMA Approval documents
- 735K+ pages of FDA Advisory Committees Meetings documents

Dedicated PK, Metabolizing enzymes and transporter data taxonomies

Data on enzymes and transporters includes genetic variations and polymorphisms

PharmaPendium is designed to provide Pharmaceutical developers superior support for more rapid development of safer and more effective drugs. It helps DMPK scientists to fail drugs faster and make informed decisions in drug candidate safety risk assessment and clinical trial planning.

Contact us to learn more about PharmaPendium:
elsevier.com/PharmaPendium

PharmaPendium is a trademark of Elsevier Limited. Copyright © 2020 Elsevier June 2020